1373503-45-7 Usage
General Description
Tert-butyl 4-((benzyloxycarbonylamino)methyl)-3,3-difluoropiperidine-1-carboxylate is a complex organic compound with a long, specific name that is derived from piperidine. The compound contains a 3,3-difluoropiperidine ring with a tert-butyl ester and a benzyloxycarbonylamino methyl group attached to it. The 3,3-difluoropiperidine moiety contains two fluorine atoms, and the benzyloxycarbonylamino methyl group is a part of the amino acid derivative. tert-butyl 4-((benzyloxycarbonylaMino)Methyl)-3,3-difluoropiperidine-1-carboxylate has potential applications in medicinal chemistry and drug synthesis due to its unique structure and functional groups. Additionally, the presence of the ester and amino acid derivative suggests that it may have pharmaceutical or biological activity.
Check Digit Verification of cas no
The CAS Registry Mumber 1373503-45-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,3,5,0 and 3 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1373503-45:
(9*1)+(8*3)+(7*7)+(6*3)+(5*5)+(4*0)+(3*3)+(2*4)+(1*5)=147
147 % 10 = 7
So 1373503-45-7 is a valid CAS Registry Number.
1373503-45-7Relevant articles and documents
TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS
-
Paragraph 0406, (2018/06/12)
Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.
1-R 1 -3, 3-difluoro-4-R 2-piperidine and its derivatives preparation method
-
, (2016/10/08)
The invention relates to a preparation method for 1-R1-3,3-difluoro-4-R2-piperidine shown as a formula (I) and derivatives thereof. In the formula (I), R1 is hydrogen, C1-C9 alkyl, aryl, benzyl, CF3CO, R4CO or R5OCO; R4 is C1-C9 alkyl, aryl or benzyl; R5 is C1-C9 alkyl, aryl or benzyl; R2 is CH2NHR6 or CH2CO2H; R6 is hydrogen, C1-C9 alkyl, aryl, benzyl, CF3CO, R4CO or R5OCO; R3 is hydrogen, C1-C9 alkyl, aryl or benzyl; and the above optional groups are not substituted or substituted by a substituted group consisting of one or more of alkyl, haloalkyl, hydroxyalkyl, halogen, alkyloxy or hydroxyl. The preparation method is characterized by comprising steps shown by a reaction formula in the specification.
